A randomized double-blind placebo controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel prednisone and bevacizumab in men with metastatic castrate resistant prostate cancer (metCRPC): Survival results of CALGB 90401
- Citation:
- J Clin Oncol vol 28 (15s) abstr 4511
- Meeting Instance:
- ASCO 2010
- Year:
- 2010
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 257
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- W. K. Kelly S. Halabi D. J. George W. M. Stadler P. W. Kantoff M. J. Morris P. J. Monk E. H. Leung E. J. Small
- Networks:
- Study
- CALGB-90401
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: